World's Best Scientists 2026 revealed!
Thomas P. Monath

Thomas P. Monath

D-Index & Metrics

Immunology

D-Index
92
Citations
23536
World Ranking
1014
National Ranking
549

Medicine

D-Index
94
Citations
25278
World Ranking
10624
National Ranking
5460

Research.com Recognitions

  • 2011 - Fellow of the American Society of Tropical Medicine and Hygiene (ASTMH)

Overview

Thomas P. Monath is affiliated with Crozet BioPharma in the United States and has contributed extensively to research in the field of medicine, with a focus on infectious diseases. Their work spans multiple specialized areas including infectious diseases, public health, epidemiology, molecular biology, and immunology.

Their research topics cover a range of subjects related to viral infections and outbreaks, with particular attention to viral infections and vectors, mosquito-borne diseases, SARS-CoV-2 and COVID-19 research, virology and viral diseases, and COVID-19 epidemiological and clinical research studies.

Among notable publication venues, Monath has frequently published in:

  • Vaccine
  • American Journal of Tropical Medicine and Hygiene
  • npj Vaccines
  • Viruses
  • The Journal of Infectious Diseases

Their collaboration network includes frequent coauthors such as:

  • Claire-Anne Siegrist
  • Peter G. Kremsner
  • Donata Medaglini
  • Tom H. M. Ottenhoff
  • Francesco Santoro

Monath's recent papers reflect their research interests and include:

  • "The Origin of COVID-19 and Why It Matters," 2020, American Journal of Tropical Medicine and Hygiene
  • "Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial," 2021, The Lancet
  • "A Randomized Dose-Escalating Phase I Trial of a Replication-Deficient Lymphocytic Choriomeningitis Virus Vector-Based Vaccine Against Human Cytomegalovirus," 2020, The Journal of Infectious Diseases
  • "A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2," 2022, Emerging Microbes & Infections
  • "High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster," 2022, The Journal of Infectious Diseases

Throughout their career, Monath has produced a significant volume of work in infectious diseases, with a total of 87 publications in medicine-related fields. They have received recognition as a Fellow of the American Society of Tropical Medicine and Hygiene (ASTMH) in 2011.

Best Publications

  • Dengue: the risk to developed and developing countries

    Thomas P. Monath

  • ICTV Virus Taxonomy Profile: Flaviviridae.

    Peter Simmonds;Paul Becher;Jens Bukh;Ernest A. Gould

  • Epidemic arboviral diseases: priorities for research and public health

    Annelies Wilder-Smith;Annelies Wilder-Smith;Duane J Gubler;Scott C Weaver;Thomas P Monath

  • Immunization of Mice with Urease Vaccine Affords Protection against Helicobacter pylori Infection in the Absence of Antibodies and Is Mediated by MHC Class II–restricted Responses

    Thomas H. Ermak;Paul J. Giannasca;Richard Nichols;Gwendolyn A. Myers

  • Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults.

    Pierre Michetti;Christianna Kreiss;Karen L. Kotloff;Nadine Porta

  • Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine

    J D Poland;C H Calisher;T P Monath;W G Downs

  • Lassa Virus Isolation from Mastomys natalensis Rodents during an Epidemic in Sierra Leone

    Thomas P. Monath;Verne F. Newhouse;Graham E. Kemp;Henry W. Setzer

  • Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.

    F. Guirakhoo;R. Weltzin;T. J. Chambers;Z.-X. Zhang

  • Safety and Efficacy of Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine Formulations in Nonhuman Primates

    F. Guirakhoo;K. Pugachev;Z. Zhang;G. Myers

  • Construction, Safety, and Immunogenicity in Nonhuman Primates of a Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine

    F. Guirakhoo;J. Arroyo;K. V. Pugachev;C. Miller

  • Oral Immunization with Recombinant Helicobacter pylori Urease Induces Secretory IgA Antibodies and Protects Mice from Challenge with Helicobacter felis

    Lee Ck;Weltzin R;Thomas Wd;Kleanthous H

  • Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea

    Stavros Sougioultzis;Lorraine Kyne;Denise Drudy;Sarah Keates

  • The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever.

    Emily S Jentes;Gilles Poumerol;Mark D Gershman;David R Hill

  • Proposed revision to the taxonomy of the genus Pestivirus, family Flaviviridae.

    Donald B. Smith;Donald B. Smith;Gregor Meyers;Jens Bukh;Ernest A. Gould

  • Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.

    Thomas P. Monath;Farshad Guirakhoo;Richard Nichols;Sutee Yoksan

  • Clinical proof of principle for ChimeriVax™: recombinant live, attenuated vaccines against flavivirus infections

    Thomas P Monath;Karen McCarthy;Philip Bedford;Casey T Johnson

  • Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1.

    J J Schlesinger;M W Brandriss;C B Cropp;T P Monath

  • ChimeriVax-West Nile Virus Live-Attenuated Vaccine: Preclinical Evaluation of Safety, Immunogenicity, and Efficacy

    Juan Arroyo;Chuck Miller;John Catalan;Gwendolyn A. Myers

  • Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.

    Farshad Guirakhoo;Scott Kitchener;Dennis Morrison;Remi Forrat

  • A live, attenuated recombinant West Nile virus vaccine

    Thomas P. Monath;Jian Liu;Niranjan Kanesa-Thasan;Gwendolyn A. Myers

  • Immunogenicity, Genetic Stability, and Protective Efficacy of a Recombinant, Chimeric Yellow Fever-Japanese Encephalitis Virus (ChimeriVax-JE) as a Live, Attenuated Vaccine Candidate against Japanese Encephalitis☆

    F. Guirakhoo;Z.-X. Zhang;T.J. Chambers;S. Delagrave

  • Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia

    Stephen B. Kennedy;Fatorma Bolay;Mark Kieh;Greg Grandits

  • Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE).

    Juan Arroyo;Farshad Guirakhoo;Sabine Fenner;Zhen-Xi Zhang

  • Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults.

    Karen L. Kotloff;Steven S. Wasserman;Genevieve A. Losonsky;William Thomas

Frequent Co-Authors

Dennis W. Trent
Dennis W. Trent The University of Texas Medical Branch at Galveston
Alan D.T. Barrett
Alan D.T. Barrett The University of Texas Medical Branch at Galveston
Richard J. Nichols
Richard J. Nichols University of Liverpool
Jean Lang
Jean Lang Sanofi (France)
Barry R. Miller
Barry R. Miller Centers for Disease Control and Prevention
Annelies Wilder-Smith
Annelies Wilder-Smith University of Bern
Sharon E. Frey
Sharon E. Frey Saint Louis University
Philip Bejon
Philip Bejon University of Oxford
John T. Roehrig
John T. Roehrig Centers for Disease Control and Prevention
J. Erin Staples
J. Erin Staples Centers for Disease Control and Prevention

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related healthcare degrees can open diverse career opportunities. Accelerated nursing programs offer a fast track into clinical roles, with several options known for their accessibility. Students can consider the easiest absn programs to get into to quickly gain a Bachelor of Science in Nursing and begin working in patient care.

Licensed Practical Nurse (LPN) programs also provide a gateway into healthcare with programs that emphasize straightforward admission processes. Discovering easy admission lpn programs can help students start their nursing careers sooner with foundational skills in patient support and monitoring.

For advanced clinical roles, nurse practitioner degrees offer expanded responsibilities. Identifying which nurse practitioner program is easiest may assist applicants seeking programs that balance quality education with manageable admissions criteria.

Mental health is another critical area within immunology-related healthcare fields. Those interested can explore the top online pmhnp programs to find respected programs that offer strong clinical placement rates, crucial for hands-on experience in psychiatric mental health nursing.

Best Scientists Citing Thomas P. Monath

Trending Scientists

Recently Published Articles